In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

immatics biotechnologies GMBH

Executive Summary

immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.

You may also be interested in...



PheneX Pharmaceuticals AG

PheneX Pharmaceuticals AG is a German biotech start-up formed by a management buy-out of certain drug discovery assets from Lion Bioscience. The firm has embraced a fee-for-service business model, aiming to leverage its expertise in nuclear receptor modulating compounds.

Cancer Vaccines: European Immunotherapy Strategies

European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel